Stem cell therapy for knee osteoarthritis is moving from marketing into measured clinical research. In 2026 a major U.S. Phase 3 trial enrolled its first patient, a Phase 2 program got underway, and researchers catalogued more than 200 stem cell trials for osteoarthritis worldwide. This article explains the 2026 trial landscape in plain language, what it does and does not prove, and why none of it changes the honest FDA picture.
224
registered stem cell-based OA trials identified in a Sept 2026 review
July 2026
when CARTISTEM's first U.S. Phase 3 participant was treated
0
stem cell products FDA-approved for osteoarthritis today
Knee osteoarthritis is the most common joint condition in the country, and it is the condition regenerative clinics see most often. That makes the knee the natural focus of clinical research, and in 2026 the volume of work is striking. A review of the global trial landscape published in September 2026 identified 224 registered stem cell-based trials for osteoarthritis, most of them targeting the knee, and described intra-articular injections as generally well tolerated, with mostly mild and self-limiting local reactions.
The biggest single development of 2026 is the U.S. Phase 3 program for CARTISTEM, an allogeneic cell therapy made from umbilical cord blood and developed by the South Korean company MEDIPOST. The FDA cleared the company's Phase 3 plan in February 2026, and the first U.S. participant was treated on July 7, 2026, in a randomized, double-blind study planned across roughly 60 sites in the United States and Canada. The program builds in part on Korean and Japanese Phase 3 data. Critically, CARTISTEM remains investigational and is not FDA-approved, but if the trial succeeds it could represent a first approval of its kind for cartilage defects due to knee osteoarthritis.
“The FDA cleared MEDIPOST's Phase 3 plan for CARTISTEM in February 2026, and the first U.S. participant was treated in July 2026 in a randomized, double-blind study across roughly 60 sites in the U.S. and Canada.”
CARTISTEM is not the only late-stage program. Steminent Biotherapeutics began a U.S. FDA-authorized Phase II clinical trial of its stem cell drug for knee osteoarthritis in March 2026, with enrollment expected at UCLA and the University of South Florida. Behind these sit dozens of earlier-phase programs, most using the patient's own bone marrow or fat-derived cells. All of them are investigational, which means they are carefully regulated studies, not treatments you can simply buy.
The largest randomized trial in the field, MILES, which enrolled roughly 480 patients, is a reminder to keep expectations humble. It found that stem cell injections did not reliably outperform standard treatments at 12 months. That result does not end the story, but it is exactly why careful, evidence-informed care matters, and why no clinic should promise that any stem cell injection will reverse arthritis. The field's own best data points to modest, variable benefit for many patients rather than guaranteed structural repair.
None of these trials change the FDA picture today: no stem cell product is approved for osteoarthritis or any orthopedic condition, and a clinic offering such treatment is working with investigational, not approved, therapy. What the 2026 landscape does give patients is a clearer, more honest frame. The science is being studied seriously, results are real but variable, and the right first step is a careful evaluation of your own knee, your imaging, and your goals, not a one-size-fits-all injection.
A note from the clinic
At Aloha Stem Cell in Honolulu we are transparent that cell-based treatments are investigational, and we recommend them only after a careful evaluation shows they could genuinely fit. Call (808) 593-2525 to talk through your knee, your imaging, and what the science really supports.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.